These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15512775)

  • 1. Tumour angiogenesis, vascular biology and enhanced drug delivery.
    Dass CR
    J Drug Target; 2004 Jun; 12(5):245-55. PubMed ID: 15512775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer angiogenesis: targeting the heel of Achilles.
    Dass CR; Choong PF
    J Drug Target; 2008 Jul; 16(6):449-54. PubMed ID: 18604657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of angiogenesis in human neoplasms: current prognostic and therapeutic implications.
    Fontanini G; Del Mastro L; Bevilacqua G
    Forum (Genova); 1998; 8(2):128-42. PubMed ID: 9666050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of angiogenesis inhibitors in tumour treatment.
    Fayette J; Soria JC; Armand JP
    Eur J Cancer; 2005 May; 41(8):1109-16. PubMed ID: 15911233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of lipoplexes for genotherapy of solid tumours: role of vascular endothelial cells.
    Dass CR; Su T
    J Pharm Pharmacol; 2000 Nov; 52(11):1301-17. PubMed ID: 11186238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumours can adapt to anti-angiogenic therapy depending on the stromal context: lessons from endothelial cell biology.
    van Kempen LC; Leenders WP
    Eur J Cell Biol; 2006 Feb; 85(2):61-8. PubMed ID: 16439306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour angiogenesis, anti-angiogenic therapy and chemotherapeutic resistance.
    Mander KA; Finnie JW
    Aust Vet J; 2018 Oct; 96(10):371-378. PubMed ID: 30255577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
    Sengupta S; Eavarone D; Capila I; Zhao G; Watson N; Kiziltepe T; Sasisekharan R
    Nature; 2005 Jul; 436(7050):568-72. PubMed ID: 16049491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.
    Pastorino F; Di Paolo D; Loi M; Becherini P; Caffa I; Zorzoli A; Marimpietri D; Carosio R; Perri P; Montaldo PG; Brignole C; Pagnan G; Ribatti D; Allen TM; Ponzoni M
    Curr Drug Targets; 2009 Oct; 10(10):1021-7. PubMed ID: 19663770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
    Cézé N; Lecomte T; Watier H
    Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 13. Tumour vascularisation: a druggable target.
    Bishop-Bailey D
    Curr Opin Pharmacol; 2009 Apr; 9(2):96-101. PubMed ID: 19056315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature.
    Dass CR
    Int J Pharm; 2003 Nov; 267(1-2):1-12. PubMed ID: 14602379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular normalisation as the stepping stone into tumour microenvironment transformation.
    Magnussen AL; Mills IG
    Br J Cancer; 2021 Aug; 125(3):324-336. PubMed ID: 33828258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 17. Therapeutic inhibition of angiogenesis.
    Zhang HT; Bicknell R
    Mol Biotechnol; 2003 Oct; 25(2):185-200. PubMed ID: 14526126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic strategies and agents in clinical trials.
    Rosen L
    Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
    Kanthou C; Tozer GM
    Expert Opin Ther Targets; 2007 Nov; 11(11):1443-57. PubMed ID: 18028009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.